Adult Dosing

Attention deficit hyperactivity disorder

Immediate release

• Start with 5 mg PO qam or bid; may increase 5 mg/day qwk until optimal response
• Usual dose: 5-40 mg/day PO div qd-tid
• Max: 40 mg/day
• Notes:
• Give first dose on awakening; administer additional doses at intervals of 4-6 hrs
• Individualize dosage according to therapeutic needs and response of the patient
• Avoid late evening doses because of the potential for insomnia

Extended release

• 20 mg PO qam
• Notes:
• Individualize dosage according to therapeutic needs and response of the patient
• May switch from IR to ER at same total daily dose qam
• Avoid afternoon doses because of the potential for insomnia
• Doses >20 mg/day are rarely more effective

Narcolepsy

Immediate release

• Start 10 mg PO qam; may increase 10 mg/day qwk until optimal response
• Usual dose: 5-60 mg/day PO div qd-tid
• Notes:
• Individualize dosage according to therapeutic needs and response of the patient
• Give first dose on awakening; administer additional doses at intervals of 4-6 hrs

Pediatric Dosing

Attention deficit hyperactivity disorder

Immediate release

• 3-5 yrs
• Start 2.5 mg PO qam; may increase 2.5 mg/day qwk until optimal response

• 6 yrs
• 5 mg PO qam or bid; may increase 5 mg/day qwk until optimal response
• Usual dose: 5-40 mg/day PO div qd-tid
• Max: 40 mg/day
• Notes:
• Give first dose on awakening; administer additional doses at intervals of 4-6 hrs
• Individualize dosage according to therapeutic needs and response of the patient
• Avoid late evening doses because of the potential for insomnia

Extended release

• 6-12 yrs
• Start 10 mg PO qam; may increase 5-10 mg/day qwk
• Max: 30 mg/day
• Notes:
• Individualize dosage according to therapeutic needs and response of the patient
• If lower initial dose is appropriate, initiate therapy with 5 mg PO qam
• May switch from IR to ER at same total daily dose qam
• Avoid afternoon doses because of the potential for insomnia

• 13-17 yrs
• Start 10 mg PO qam; may increase 20 mg/day after 1 week if symptoms are not controlled adequately
• Notes:
• Individualize dosage according to therapeutic needs and response of the patient
• May convert from IR to ER at same total daily dose qam
• Avoid afternoon doses because of the potential for insomnia
• Doses >20 mg/day are rarely more effective

Narcolepsy

Immediate release

• 6-12 yrs
• Start 5 mg PO qam; may increase 5 mg/day qwk until optimal response
• Usual dose: 5-60 mg/day PO div qd-tid
• Notes:
• Individualize dosage according to therapeutic needs and response of the patient
• Give first dose on awakening; administer additional doses at intervals of 4-6 hrs

• >12 yrs
• Start 10 mg PO qam; may increase 10 mg/day qwk until optimal response
• Usual dose: 5-60 mg/day PO div qd-tid
• Notes:
• Individualize dosage according to therapeutic needs and response of the patient
• Give first dose on awakening; administer additional doses at intervals of 4-6 hrs

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of attention deficit hyperactivity disorder (ECAPS, TABS)
• Treatment of narcolepsy (TABS)

• Hypersensitivity to any of the ingredients of the product
• History of drug abuse
• Cardiac structural abnormalities
• Cardiomyopathy
• Severe arrhythmias
• Moderate-severe hypertension
• Glaucoma
• Advanced arteriosclerosis
• Symptomatic cardiovascular disease
• Hyperthyroidism
• Agitation
• Idiosyncracy or hypersensitivity response to sympathomimetics
• Use during or within 14 days following the administration of monoamine oxidase inhibitors
• Lactation
• Abrupt withdrawal

• Amphetamine component of this combination drug exhibits high potential for abuse; avoid long-term therapy as drug dependence may occur. Prescribe/dispense this drug sparingly. Special attention must be given to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others
• Sudden death and serious cardiovascular adverse reactions may occur with misuse of amphetamines

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• Sudden death and pre-existing structural cardiac abnormalities or other serious heart problems are associated with CNS stimulant therapy, even at usual doses. Children and adolescents with structural cardiac abnormalities or other serious heart problems are more prone to sudden death. Avoid using this therapy in children or adolescents with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of the drug. Adults are more susceptible for development of cardiovascular related events. Modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm) may occur in patients receiving stimulant medications; monitor patients for larger changes in heart rate and blood pressure. Carefully undertake history including assessment for a familial history of sudden death or ventricular arrhythmia. Perform physical examination to assess for the presence of cardiac disease; perform electrocardiogram and echocardiogram if findings suggest presence of cardiac disease. Immediately perform cardiac evaluation on developing symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease in patients undergoing therapy
• Patients with preexisting psychotic disorder are prone for development of exacerbating symptoms of behavior disturbance and thought disorder
• Mixed manic episode may occur in ADHD patients with comorbid bipolar disorders receiving CNS stimulants; adequately screen patients with comorbid depressive symptoms for risk of developing bipolar disorder. Undertake a detailed psychiatric history, including a familial history of suicide, bipolar disorder, and depression
• Treatment-emergent psychotic or manic symptoms including hallucinations, delusional thinking, or mania may occur in children and adolescents without prior history of psychotic illness or mania. Discontinuation of therapy may be essential in such patients. Aggressive behavior or hostility may occur is in children and adolescents with ADHD during therapy; monitor patients for the appearance of or worsening of aggressive behavior or hostility
• Long-term suppression of growth may occur during therapy; monitor growth in children during treatment with stimulants and interrupt therapy in patients who are not growing or gaining weight as expected
• Convulsive threshold may be lowered in patients with prior history of seizures, patients with prior EEG abnormalities in the absence of seizures, and very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. Discontinue therapy in the presence of seizures
• Difficulties with accommodation and blurring of vision may occur during therapy
• Prescribe or dispense the least amount of amphetamine at one time in order to minimize the possibility of overdosage
• Exacerbation of motor and phonic tics and Tourette’s syndrome may occur during therapy; perform clinical evaluation for tics and Tourette’s syndrome in patients and their families before initiating therapy
• Therapy is associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms usually improve after reduction in dose or discontinuation of therapy

Cautions: Use cautiously in

• Geriatric patients
• History of cardiovascular disease
• Mild hypertension
• Increase in heart rate
• Heart failure
• Recent myocardial infarction
• Ventricular arrhythmia
• Psychosis
• History/risk of seizure
• Patients using other sympathomimetic drugs
• ADHD patients with comorbid bipolar disorder

Supplemental Patient Information

• Caution patients against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a vehicle
• Inform patients, their families, and their caregivers about the potential benefits and risks associated with this drug and counsel them in its appropriate use
• Instruct patients to report to their physician about any numbness, pain, skin color change, or sensitivity to temperature in fingers or toes

Pregnancy Category:C

Breastfeeding: In dosages prescribed for medical indications, some evidence indicates that amphetamine/dextroamphetamine does not affect nursing infants adversely. The effect of amphetamine/dextroamphetamine in milk on the neurological development of the infant has not been well established. Large dosages might interfere with milk production, especially in women whose lactation is not well established. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 24 June 2011). Manufacturer advises mothers taking this combination drug to refrain from nursing.

• CNS: Drug abuse/dependency, Tourette syndrome, exacerbation of motor and phonic tics, seizures, insomnia, anxiety, headache, emotional lability, nervousness, asthenia, dizziness, tremor, dyskinesia, overstimulation, restlessness, euphoria, dysphoria, paresthesia
• PSYCHIATRY: Depression, agitation, psychosis, mania, aggressive behavior
• CV: Severe hypertension, MI, stroke, sudden death, cardiomyopathy (prolonged use), palpitations, tachycardia
• ENDO: Growth suppression, changes in libido, impotence
• EENT: Visual disturbances
• GI: Abdominal pain, dry mouth, nausea, vomiting, diarrhea, dyspepsia, constipation, unpleasant taste
• METABOLIC: Anorexia, weight loss
• GU: Urinary tract infections
• HYPERSENSITIVITY: Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, rash, angioedema, anaphylaxis, hypersensitivity reactions
• REPRODUCTIVE: Frequent or prolonged erections
• MISC: Fever, infection, accidental injury, withdrawal if abruptly discontinued (long-term use)

Amphetamine

• CNS stimulant (sympathomimetic); precise mechanism of action in ADHD is unknown; blocks the re-uptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space
• Metabolized by liver; CYP450: CYP2D6
• Primarily excreted in urine
• Half-life: 10 hrs

Dextroamphetamine

• CNS stimulant (sympathomimetic); precise mechanism of action in ADHD is unknown; blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space
• Rapidly absorbed from the gastrointestinal tract
• Metabolized by liver; CYP450: CYP2D6
• Excreted in urine
• Half-life:
• 6-12 yrs: 9 hrs
• 13-17 yrs: 11 hrs
• Adults: 10 hrs

US Trade Name(s)

• Adderall XR 5
• Adderall XR 10
• Adderall XR 15
• Adderall XR 20
• Adderall XR 25
• Adderall XR 30

US Availability

amphetamine/dextroamphetamine (generic)

• TABS:
• 2.5 mg/2.5 mg
• 3.75 mg/3.75 mg
• 5 mg/5 mg
• 6.25 mg/6.25 mg
• 7.5 mg/7.5 mg
• 10 mg/10 mg
• 15 mg/15 mg

• ECAPS:
• 2.5 mg/2.5 mg
• 5 mg/5 mg
• 7.5 mg/7.5 mg
• 10 mg/10 mg
• 12.5 mg/12.5 mg
• 15 mg/15 mg

Adderall XR 5 (amphetamine/dextroamphetamine)

• ECAPS: 2.5 mg/2.5 mg

Adderall XR 10 (amphetamine/dextroamphetamine)

• ECAPS: 5 mg/5 mg

Adderall XR 15 (amphetamine/dextroamphetamine)

• ECAPS: 7.5 mg/7.5 mg

Adderall XR 20 (amphetamine/dextroamphetamine)

• ECAPS: 10 mg/10 mg

Adderall XR 25 (amphetamine/dextroamphetamine)

• ECAPS: 12.5 mg/12.5 mg

Adderall XR 30 (amphetamine/dextroamphetamine)

• ECAPS: 15 mg/15 mg

Canadian Trade Name(s)

• Adderall XR 5
• Adderall XR 10
• Adderall XR 15
• Adderall XR 20
• Adderall XR 25
• Adderall XR 30

Canadian Availability

Adderall XR 5 (amphetamine/dextroamphetamine)

• ECAPS: 2.5 mg/2.5 mg

Adderall XR 10 (amphetamine/dextroamphetamine)

• ECAPS: 5 mg/5 mg

Adderall XR 15 (amphetamine/dextroamphetamine)

• ECAPS: 7.5 mg/7.5 mg

Adderall XR 20 (amphetamine/dextroamphetamine)

• ECAPS: 10 mg/10 mg

Adderall XR 25 (amphetamine/dextroamphetamine)

• ECAPS: 12.5 mg/12.5 mg

Adderall XR 30 (amphetamine/dextroamphetamine)

• ECAPS: 15 mg/15 mg

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Psychiatric

CNS Stimulants

Amphetamines

• Adderall 10 MG Oral Tablet (Physicians Total Care, Inc.)
• Adderall 10 MG Oral Tablet (Shire US Inc.)
• Adderall 12.5 MG Oral Tablet (Shire US Inc.)
• Adderall 15 MG Oral Tablet (Shire US Inc.)
• Adderall 20 MG Oral Tablet (Physicians Total Care, Inc.)
• Adderall 20 MG Oral Tablet (Shire US Inc.)
• Adderall 30 MG Oral Tablet (Physicians Total Care, Inc.)
• Adderall 30 MG Oral Tablet (Shire US Inc.)
• Adderall 5 MG Oral Tablet (Physicians Total Care, Inc.)
• Adderall 5 MG Oral Tablet (Shire US Inc.)
• Adderall 7.5 MG Oral Tablet (Shire US Inc.)
• Adderall XR 10 MG 24 HR Extended Release Capsule (Shire US Inc.)
• Adderall XR 15 MG 24 HR Extended Release Capsule (Shire US Inc.)
• Adderall XR 20 MG 24 HR Extended Release Capsule (Shire US Inc.)
• Adderall XR 25 MG 24 HR Extended Release Capsule (Shire US Inc.)
• Adderall XR 30 MG 24 HR Extended Release Capsule (Shire US Inc.)
• Adderall XR 5 MG 24 HR Extended Release Capsule (Shire US Inc.)
• Amphetamine aspartate 1.25 MG / Amphetamine Sulfate 1.25 MG / Dextroamphetamine saccharate 1.25 MG / Dextroamphetamine Sulfate 1.25 MG Oral Tablet (Barr Laboratories Inc.)
• Amphetamine aspartate 1.25 MG / Amphetamine Sulfate 1.25 MG / Dextroamphetamine saccharate 1.25 MG / Dextroamphetamine Sulfate 1.25 MG Oral Tablet (Corepharma LLC)
• Amphetamine aspartate 1.25 MG / Amphetamine Sulfate 1.25 MG / Dextroamphetamine saccharate 1.25 MG / Dextroamphetamine Sulfate 1.25 MG Oral Tablet (Mallinckrodt Inc.)
• Amphetamine aspartate 1.25 MG / Amphetamine Sulfate 1.25 MG / Dextroamphetamine saccharate 1.25 MG / Dextroamphetamine Sulfate 1.25 MG Oral Tablet (Mutual Pharmaceutical Company)
• Amphetamine aspartate 1.25 MG / Amphetamine Sulfate 1.25 MG / Dextroamphetamine saccharate 1.25 MG / Dextroamphetamine Sulfate 1.25 MG Oral Tablet (Physicians Total Care, Inc.)
• Amphetamine aspartate 1.25 MG / Amphetamine Sulfate 1.25 MG / Dextroamphetamine saccharate 1.25 MG / Dextroamphetamine Sulfate 1.25 MG Oral Tablet (Sandoz Inc)
• Amphetamine aspartate 1.25 MG / Amphetamine Sulfate 1.25 MG / Dextroamphetamine saccharate 1.25 MG / Dextroamphetamine Sulfate 1.25 MG Oral Tablet (Teva Pharmaceuticals USA)
• Amphetamine aspartate 1.25 MG / amphetamine sulfate 1.25 MG / dextroamphetamine saccharate 1.25 MG / dextroamphetamine sulfate 1.25 MG 24 HR Extended Release Capsule (Global Pharmaceuticals, Division of Impax Laboratories Inc.)
• Amphetamine aspartate 1.875 MG / amphetamine saccharate 1.875 MG / dextroamphetamine saccharate 1.875 MG / dextroamphetamine sulfate 1.875 MG Oral Tablet (Barr Laboratories Inc.)
• Amphetamine aspartate 1.875 MG / amphetamine saccharate 1.875 MG / dextroamphetamine saccharate 1.875 MG / dextroamphetamine sulfate 1.875 MG Oral Tablet (Mallinckrodt Inc.)
• Amphetamine aspartate 1.875 MG / amphetamine saccharate 1.875 MG / dextroamphetamine saccharate 1.875 MG / dextroamphetamine sulfate 1.875 MG Oral Tablet (Mutual Pharmaceutical Company)
• Amphetamine aspartate 2.5 MG / Amphetamine Sulfate 2.5 MG / Dextroamphetamine saccharate 2.5 MG / Dextroamphetamine Sulfate 2.5 MG Oral Tablet (Barr Laboratories Inc.)
• Amphetamine aspartate 2.5 MG / Amphetamine Sulfate 2.5 MG / Dextroamphetamine saccharate 2.5 MG / Dextroamphetamine Sulfate 2.5 MG Oral Tablet (Corepharma LLC)
• Amphetamine aspartate 2.5 MG / Amphetamine Sulfate 2.5 MG / Dextroamphetamine saccharate 2.5 MG / Dextroamphetamine Sulfate 2.5 MG Oral Tablet (Mallinckrodt Inc.)
• Amphetamine aspartate 2.5 MG / Amphetamine Sulfate 2.5 MG / Dextroamphetamine saccharate 2.5 MG / Dextroamphetamine Sulfate 2.5 MG Oral Tablet (Mutual Pharmaceutical Company)
• Amphetamine aspartate 2.5 MG / Amphetamine Sulfate 2.5 MG / Dextroamphetamine saccharate 2.5 MG / Dextroamphetamine Sulfate 2.5 MG Oral Tablet (Physicians Total Care, Inc.)
• Amphetamine aspartate 2.5 MG / Amphetamine Sulfate 2.5 MG / Dextroamphetamine saccharate 2.5 MG / Dextroamphetamine Sulfate 2.5 MG Oral Tablet (Sandoz Inc)
• Amphetamine aspartate 2.5 MG / Amphetamine Sulfate 2.5 MG / Dextroamphetamine saccharate 2.5 MG / Dextroamphetamine Sulfate 2.5 MG Oral Tablet (Teva Pharmaceuticals USA)
• Amphetamine aspartate 2.5 MG / amphetamine sulfate 2.5 MG / dextroamphetamine saccharate 2.5 MG / dextroamphetamine sulfate 2.5 MG 24 HR Extended Release Capsule (Global Pharmaceuticals, Division of Impax Laboratories Inc.)
• Amphetamine aspartate 2.5 MG / amphetamine sulfate 2.5 MG / dextroamphetamine saccharate 2.5 MG / dextroamphetamine sulfate 2.5 MG 24 HR Extended Release Capsule (Physicians Total Care, Inc.)
• Amphetamine aspartate 3.125 MG / amphetamine sulfate 3.125 MG / dextroamphetamine saccharate 3.125 MG / dextroamphetamine sulfate 3.125 MG Oral Tablet (Barr Laboratories Inc.)
• Amphetamine aspartate 3.125 MG / amphetamine sulfate 3.125 MG / dextroamphetamine saccharate 3.125 MG / dextroamphetamine sulfate 3.125 MG Oral Tablet (Mallinckrodt Inc.)
• Amphetamine aspartate 3.125 MG / amphetamine sulfate 3.125 MG / dextroamphetamine saccharate 3.125 MG / dextroamphetamine sulfate 3.125 MG Oral Tablet (Mutual Pharmaceutical Company)
• Amphetamine aspartate 3.125 MG / amphetamine sulfate 3.125 MG / dextroamphetamine saccharate 3.125 MG / dextroamphetamine sulfate 3.125 MG Oral Tablet (Physicians Total Care, Inc.)
• Amphetamine aspartate 3.75 MG / Amphetamine Sulfate 3.75 MG / Dextroamphetamine saccharate 3.75 MG / Dextroamphetamine Sulfate 3.75 MG Oral Tablet (Barr Laboratories Inc.)
• Amphetamine aspartate 3.75 MG / Amphetamine Sulfate 3.75 MG / Dextroamphetamine saccharate 3.75 MG / Dextroamphetamine Sulfate 3.75 MG Oral Tablet (Mallinckrodt Inc.)
• Amphetamine aspartate 3.75 MG / Amphetamine Sulfate 3.75 MG / Dextroamphetamine saccharate 3.75 MG / Dextroamphetamine Sulfate 3.75 MG Oral Tablet (Mutual Pharmaceutical Company)
• Amphetamine aspartate 3.75 MG / amphetamine sulfate 3.75 MG / dextroamphetamine saccharate 3.75 MG / dextroamphetamine sulfate 3.75 MG 24 HR Extended Release Capsule (Global Pharmaceuticals, Division of Impax Laboratories Inc.)
• Amphetamine aspartate 5 MG / Amphetamine Sulfate 5 MG / Dextroamphetamine saccharate 5 MG / Dextroamphetamine Sulfate 5 MG Oral Tablet (Barr Laboratories Inc.)
• Amphetamine aspartate 5 MG / Amphetamine Sulfate 5 MG / Dextroamphetamine saccharate 5 MG / Dextroamphetamine Sulfate 5 MG Oral Tablet (Corepharma LLC)
• Amphetamine aspartate 5 MG / Amphetamine Sulfate 5 MG / Dextroamphetamine saccharate 5 MG / Dextroamphetamine Sulfate 5 MG Oral Tablet (Mallinckrodt Inc.)
• Amphetamine aspartate 5 MG / Amphetamine Sulfate 5 MG / Dextroamphetamine saccharate 5 MG / Dextroamphetamine Sulfate 5 MG Oral Tablet (Mutual Pharmaceutical Company)
• Amphetamine aspartate 5 MG / Amphetamine Sulfate 5 MG / Dextroamphetamine saccharate 5 MG / Dextroamphetamine Sulfate 5 MG Oral Tablet (Physicians Total Care, Inc.)
• Amphetamine aspartate 5 MG / Amphetamine Sulfate 5 MG / Dextroamphetamine saccharate 5 MG / Dextroamphetamine Sulfate 5 MG Oral Tablet (Sandoz Inc)
• Amphetamine aspartate 5 MG / Amphetamine Sulfate 5 MG / Dextroamphetamine saccharate 5 MG / Dextroamphetamine Sulfate 5 MG Oral Tablet (Teva Pharmaceuticals USA)
• Amphetamine aspartate 5 MG / amphetamine sulfate 5 MG / dextroamphetamine saccharate 5 MG / dextroamphetamine sulfate 5 MG 24 HR Extended Release Capsule (Global Pharmaceuticals, Division of Impax Laboratories Inc.)
• Amphetamine aspartate 5 MG / amphetamine sulfate 5 MG / dextroamphetamine saccharate 5 MG / dextroamphetamine sulfate 5 MG 24 HR Extended Release Capsule (Physicians Total Care, Inc.)
• Amphetamine aspartate 6.25 MG / amphetamine sulfate 6.25 MG / dextroamphetamine saccharate 6.25 MG / dextroamphetamine sulfate 6.25 MG 24 HR Extended Release Capsule (Global Pharmaceuticals, Division of Impax Laboratories Inc.)
• Amphetamine aspartate 6.25 MG / amphetamine sulfate 6.25 MG / dextroamphetamine saccharate 6.25 MG / dextroamphetamine sulfate 6.25 MG 24 HR Extended Release Capsule (Physicians Total Care, Inc.)
• Amphetamine aspartate 7.5 MG / Amphetamine Sulfate 7.5 MG / Dextroamphetamine saccharate 7.5 MG / Dextroamphetamine Sulfate 7.5 MG Oral Tablet (Barr Laboratories Inc.)
• Amphetamine aspartate 7.5 MG / Amphetamine Sulfate 7.5 MG / Dextroamphetamine saccharate 7.5 MG / Dextroamphetamine Sulfate 7.5 MG Oral Tablet (Corepharma LLC)
• Amphetamine aspartate 7.5 MG / Amphetamine Sulfate 7.5 MG / Dextroamphetamine saccharate 7.5 MG / Dextroamphetamine Sulfate 7.5 MG Oral Tablet (Mallinckrodt Inc.)
• Amphetamine aspartate 7.5 MG / Amphetamine Sulfate 7.5 MG / Dextroamphetamine saccharate 7.5 MG / Dextroamphetamine Sulfate 7.5 MG Oral Tablet (Mutual Pharmaceutical Company)
• Amphetamine aspartate 7.5 MG / Amphetamine Sulfate 7.5 MG / Dextroamphetamine saccharate 7.5 MG / Dextroamphetamine Sulfate 7.5 MG Oral Tablet (Physicians Total Care, Inc.)
• Amphetamine aspartate 7.5 MG / Amphetamine Sulfate 7.5 MG / Dextroamphetamine saccharate 7.5 MG / Dextroamphetamine Sulfate 7.5 MG Oral Tablet (Sandoz Inc)
• Amphetamine aspartate 7.5 MG / Amphetamine Sulfate 7.5 MG / Dextroamphetamine saccharate 7.5 MG / Dextroamphetamine Sulfate 7.5 MG Oral Tablet (Teva Pharmaceuticals USA)
• Amphetamine aspartate 7.5 MG / amphetamine sulfate 7.5 MG / dextroamphetamine saccharate 7.5 MG / dextroamphetamine sulfate 7.5 MG 24 HR Extended Release Capsule (Global Pharmaceuticals, Division of Impax Laboratories Inc.)
• Amphetamine aspartate 7.5 MG / amphetamine sulfate 7.5 MG / dextroamphetamine saccharate 7.5 MG / dextroamphetamine sulfate 7.5 MG 24 HR Extended Release Capsule (Physicians Total Care, Inc.)